Repositioning Candidate Details
| Candidate ID: | R0156 |
| Source ID: | DB00464 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Sodium tetradecyl sulfate |
| Synonyms: | 7-Ethyl-2-methyl-4-undecanol sulfate sodium salt; 7-ethyl-2-methyl-4-undecanolsulfate, sodium salt; Sodium 2-methyl-7-ethylundecanol-4-sulfate; Sodium 7-ethyl-2-methyl-4-undecanol sulfate; Sodium tetradecyl sulfate; Sodium tetradecyl sulphate; Sodium tetradecylsulfate; STS; Tetradecyl sodium sulfate |
| Molecular Formula: | C14H29NaO4S |
| SMILES: | [Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O |
| Structure: |
|
| DrugBank Description: | An anionic surface-active agent used for its wetting properties in industry and used in medicine as an irritant and sclerosing agent for hemorrhoids and varicose veins. |
| CAS Number: | 139-88-8 |
| Molecular Weight: | 316.43 |
| DrugBank Indication: | For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. |
| DrugBank Pharmacology: | Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent. |
| DrugBank MoA: | Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation. |
| Targets: | Vitamin K-dependent protein C inhibitor; Vitamin K-dependent protein S inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|